Literature DB >> 23943161

Preventive effects of conservative treatment with short-term teriparatide on the progression of vertebral body collapse after osteoporotic vertebral compression fracture.

J-H Park1, K-C Kang, D-E Shin, Y-G Koh, J-S Son, B-H Kim.   

Abstract

UNLABELLED: The progression of fractured vertebral collapse is not rare after a conservative treatment of vertebral compression fracture (VCF). Teriparatide has been shown to directly stimulate bone formation and improve bone density, but there is a lack of evidence regarding its use in fracture management. Conservative treatment with short-term teriparatide is effective for decreasing the progression of fractured vertebral body collapse.
INTRODUCTION: Few studies have reported on the prevention of collapsed vertebral body progression after osteoporotic VCF. Teriparatide rapidly enhances bone formation and increases bone strength. This study evaluated preventive effects of short-term teriparatide on the progression of vertebral body collapse after osteoporotic VCF.
METHODS: Radiographs of 68 women with single-level osteoporotic VCF at thoracolumbar junction (T11-L2) were reviewed. Among them, 32 patients were treated conservatively with teriparatide (minimum 3 months) (group I), and 36 were treated with antiresorptive (group II). We measured kyphosis and wedge angle of the fractured vertebral body, and ratios of anterior, middle, and posterior heights of the collapsed body to posterior height of a normal upper vertebra were determined. The degree of collapse progression was compared between two groups.
RESULTS: The progression of fractured vertebral body collapse was shown in both groups, but the degree of progression was significantly lower in group I than in group II. At the last follow-up, mean increments of kyphosis and wedge angle were significantly lower in group I (4.0° ± 4.2° and 3.6° ± 3.6°) than in group II (6.8° ± 4.1° and 5.8° ± 3.5°) (p = 0.032 and p = 0.037). Decrement percentages of anterior and middle border height were significantly lower in group I (9.6 ± 10.3 and 7.4 ± 7.5 %) than in group II (18.1 ± 9.7 and 13.8 ± 12.2 %) (p = 0.001 and p = 0.025), but not in posterior height (p = 0.086).
CONCLUSIONS: In female patients with single-level osteoporotic VCF at the thoracolumbar junction, short-term teriparatide treatment did not prevent but did decrease the progression of fractured vertebral body collapse.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23943161     DOI: 10.1007/s00198-013-2458-7

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  25 in total

1.  Cement leakage in percutaneous vertebroplasty for osteoporotic vertebral compression fractures: identification of risk factors.

Authors:  Marc J Nieuwenhuijse; Arian R Van Erkel; P D Sander Dijkstra
Journal:  Spine J       Date:  2011-09-01       Impact factor: 4.166

2.  Treatment of repeated and multiple new-onset osteoporotic vertebral compression fractures with teriparatide.

Authors:  Po-Hsun Tu; Zhuo-Hao Liu; Shih-Tseng Lee; Jyi-Feng Chen
Journal:  J Clin Neurosci       Date:  2012-02-15       Impact factor: 1.961

3.  Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis.

Authors:  J H Krege; X Wan
Journal:  Bone       Date:  2011-10-22       Impact factor: 4.398

4.  Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women.

Authors:  Peter Peichl; Lukas A Holzer; Richard Maier; Gerold Holzer
Journal:  J Bone Joint Surg Am       Date:  2011-09-07       Impact factor: 5.284

5.  Comparison of the therapeutic effect of teriparatide with that of combined vertebroplasty with antiresorptive agents for the treatment of new-onset adjacent vertebral compression fracture after percutaneous vertebroplasty.

Authors:  Chen-Hsing Su; Po-Hsun Tu; Tao-Chieh Yang; Yuan-Yun Tseng
Journal:  J Spinal Disord Tech       Date:  2013-06

Review 6.  Meta-analysis of vertebral augmentation compared with conservative treatment for osteoporotic spinal fractures.

Authors:  Paul A Anderson; Alexander B Froyshteter; William L Tontz
Journal:  J Bone Miner Res       Date:  2013-02       Impact factor: 6.741

7.  Implications for fracture healing of current and new osteoporosis treatments: an ESCEO consensus paper.

Authors:  J Goldhahn; J-M Féron; J Kanis; S Papapoulos; J-Y Reginster; R Rizzoli; W Dere; B Mitlak; Y Tsouderos; S Boonen
Journal:  Calcif Tissue Int       Date:  2012-03-28       Impact factor: 4.333

Review 8.  [Back pain and neurological deficits in osteoporotic spinal fractures].

Authors:  K Kaneda; M Ito
Journal:  Hokkaido Igaku Zasshi       Date:  1997-07

9.  Risk factors affecting progressive collapse of acute osteoporotic spinal fractures.

Authors:  K Y Ha; Y H Kim
Journal:  Osteoporos Int       Date:  2012-07-03       Impact factor: 4.507

10.  Kyphosis correction and height restoration effects of percutaneous vertebroplasty.

Authors:  Michael Mu Huo Teng; Chao-Jung Wei; Liang-Chen Wei; Chao-Bao Luo; Jiing-Feng Lirng; Feng-Chi Chang; Chien-Lin Liu; Cheng-Yen Chang
Journal:  AJNR Am J Neuroradiol       Date:  2003-10       Impact factor: 3.825

View more
  13 in total

Review 1.  Conservative management of osteoporotic vertebral fractures: an update.

Authors:  A Slavici; M Rauschmann; C Fleege
Journal:  Eur J Trauma Emerg Surg       Date:  2016-12-26       Impact factor: 3.693

2.  Aggravation of spinal cord compromise following new osteoporotic vertebral compression fracture prevented by teriparatide in patients with surgical contraindications.

Authors:  Y Zhao; R Xue; N Shi; Y Xue; Y Zong; W Lin; B Pei; C Sun; R Fan; Y Jiang
Journal:  Osteoporos Int       Date:  2016-05-31       Impact factor: 4.507

3.  Comparison of once-weekly teriparatide and alendronate against new osteoporotic vertebral fractures at week 12.

Authors:  Satoshi Ikeda; Eiichiro Nakamura; Kenichiro Narusawa; Fumio Fukuda; Hidehiro Matsumoto; Kenichiro Nakai; Takeshi Sakata; Toru Yoshioka; Yoshihisa Fujino; Akinori Sakai
Journal:  J Bone Miner Metab       Date:  2019-07-11       Impact factor: 2.626

Review 4.  A systematic review on the use of daily subcutaneous administration of teriparatide for treatment of patients with osteoporosis at high risk for fracture in Asia.

Authors:  J F Chen; K H Yang; Z L Zhang; H C Chang; Y Chen; H Sowa; S Gürbüz
Journal:  Osteoporos Int       Date:  2014-08-20       Impact factor: 4.507

5.  The effect of teriparatide to alleviate pain and to prevent vertebral collapse after fresh osteoporotic vertebral fracture.

Authors:  Hiroyuki Tsuchie; Naohisa Miyakoshi; Yuji Kasukawa; Tomio Nishi; Hidekazu Abe; Toyohito Segawa; Yoichi Shimada
Journal:  J Bone Miner Metab       Date:  2015-03-14       Impact factor: 2.626

6.  At least one cyclic teriparatide administration can be helpful to delay initial onset of a new osteoporotic vertebral compression fracture.

Authors:  Kyung Soo Suk; Hwan Mo Lee; Seong-Hwan Moon; Hee June Kim; Hak Sun Kim; Jin-Oh Park; Byung Ho Lee
Journal:  Yonsei Med J       Date:  2014-11       Impact factor: 2.759

7.  Does spinopelvic alignment affect the union status in thoracolumbar osteoporotic vertebral compression fracture?

Authors:  Akira Iwata; Masahiro Kanayama; Fumihiro Oha; Tomoyuki Hashimoto; Norimasa Iwasaki
Journal:  Eur J Orthop Surg Traumatol       Date:  2016-08-30

8.  Can Three Months of Teriparatide Be One of Treatment Options for Osteoporotic Vertebral Compression Fracture Patients?

Authors:  Jung Hoon Kang; Sang Mi Yang; Soo Bin Im; Je Hoon Jeong
Journal:  Korean J Neurotrauma       Date:  2019-04-25

9.  Fracture healing: a consensus report from the International Osteoporosis Foundation Fracture Working Group.

Authors:  S L Silverman; E S Kupperman; S V Bukata
Journal:  Osteoporos Int       Date:  2016-04-25       Impact factor: 4.507

10.  Clinical and radiological outcomes of conservative treatment after stable post-traumatic thoracolumbar fractures in elderly: Is it really best option for all elderly patients?

Authors:  Deniz Cankaya; Serdar Yilmaz; Alper Deveci; Abdurrahim Dundar; Burak Yoldas; Ali Toprak; Yalcın Tabak
Journal:  Ann Med Surg (Lond)       Date:  2015-09-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.